CAH vs COR
Cardinal Health Inc. and Cencora, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CAH | COR |
|---|---|---|
| Revenue | $254.2B | $321.3B |
| Net income | $1.7B | $1.6B |
| Gross margin | 3.8% | 3.6% |
| Net margin | 0.7% | 0.5% |
| Return on equity | — | 144.3% |
| Diluted EPS | $7.23 | $7.96 |
| Dividend / share | $2.04 | $2.20 |
| Payout ratio | 28.6% | 28.1% |
| Free cash flow | $4.5B | $3.2B |
| Equity | $-2.9B | $1.5B |
| Net debt / equity | — | 2.19× |
| Current ratio | 0.88× | 0.90× |
| Revenue CAGR 5y | 9.4% | 11.1% |
| Profit CAGR 5y | 22.9% | — |
COR bills 1.3× the revenue of CAH, and CAH keeps more of each dollar of revenue as profit (0.7% against 0.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | CAH | COR |
|---|---|---|
| FY2025 | $254.2B | $321.3B |
| FY2024 | $222.6B | $294.0B |
| FY2023 | $226.8B | $262.2B |
| FY2022 | $205.0B | $238.6B |
| FY2021 | $181.3B | $214.0B |
| FY2020 | $162.5B | $189.9B |
| FY2019 | $152.9B | $179.6B |
| FY2018 | $145.5B | $167.9B |
| FY2017 | $136.8B | $153.1B |
| FY2016 | $130.0B | $146.8B |
Net income by year
Bottom line
| Fiscal year | CAH | COR |
|---|---|---|
| FY2025 | $1.7B | $1.6B |
| FY2024 | $1.6B | $1.5B |
| FY2023 | $852.0M | $1.7B |
| FY2022 | $330.0M | $1.7B |
| FY2021 | $-938.0M | $1.5B |
| FY2020 | $611.0M | $-3.4B |
| FY2019 | $-3.7B | $855.4M |
| FY2018 | $1.4B | $1.7B |
| FY2017 | $256.0M | $364.5M |
| FY2016 | $1.3B | $1.4B |